Clicky

Adicet Bio, Inc.(ACET)

Description: Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.


Keywords: Medicine Biotechnology Cancer Clinical Medicine Disease Immune System Antibodies Cancer Immunotherapy Antigen Chimeric Antigen Receptor T Cell T Cell Therapies For Cancer Chimeric Antigen Receptor Adoptive Cell Transfer Immune Response

Home Page: www.adicetbio.com

ACET Technical Analysis

200 Clarendon Street
Boston, MA 02116
United States
Phone: 650 503 9095


Officers

Name Title
Mr. Chen Schor BA, CPA, CPA, M.B.A., MBA CEO, Pres & Director
Dr. Aya Jakobovits Ph.D. Founder & Independent Director
Mr. Brian Nicholas Harvey Chief Financial Officer
Dr. Francesco Galimi M.D., Ph.D. Chief Medical Officer & Sr. VP
Dr. Donald Healey Chief Technology Officer
Dr. Blake Aftab Ph.D. Sr. VP & Chief Scientific Officer
Ms. Amy Locke Head of HR
Dr. Nancy L. Boman M.D., Ph.D. Sr. VP & Chief Regulatory Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.3297
Price-to-Sales TTM: 13.9986
IPO Date: 2018-01-26
Fiscal Year End: June
Full Time Employees: 86
Back to stocks